Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. [electronic resource]
Producer: 20110215Description: 5407-14 p. digitalISSN:- 0008-543X
- Aged
- Antibiotics, Antineoplastic -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Clinical Trials, Phase III as Topic
- Disease-Free Survival
- Doxorubicin -- therapeutic use
- Endometrial Neoplasms -- drug therapy
- Female
- Humans
- Middle Aged
- Randomized Controlled Trials as Topic
- Recurrence
- Salvage Therapy
- Survival Analysis
- Time Factors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.